- Home
- GCBC vs ATXS Comparison
GCBC vs ATXS Comparison
Compare GCBC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCBC
- ATXS
- Stock Information
- Founded
- GCBC 1889
- ATXS 2008
- Country
- GCBC United States
- ATXS United States
- Employees
- GCBC N/A
- ATXS N/A
- Industry
- GCBC Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- GCBC Finance
- ATXS Health Care
- Exchange
- GCBC Nasdaq
- ATXS Nasdaq
- Market Cap
- GCBC 452.9M
- ATXS 401.2M
- IPO Year
- GCBC 1998
- ATXS 2015
- Fundamental
- Price
- GCBC $27.19
- ATXS $6.81
- Analyst Decision
- GCBC
- ATXS Strong Buy
- Analyst Count
- GCBC 0
- ATXS 6
- Target Price
- GCBC N/A
- ATXS $25.67
- AVG Volume (30 Days)
- GCBC 20.6K
- ATXS 244.9K
- Earning Date
- GCBC 01-22-2025
- ATXS 03-03-2025
- Dividend Yield
- GCBC 1.32%
- ATXS N/A
- EPS Growth
- GCBC N/A
- ATXS N/A
- EPS
- GCBC 1.54
- ATXS N/A
- Revenue
- GCBC $65,848,000.00
- ATXS N/A
- Revenue This Year
- GCBC N/A
- ATXS N/A
- Revenue Next Year
- GCBC N/A
- ATXS N/A
- P/E Ratio
- GCBC $17.66
- ATXS N/A
- Revenue Growth
- GCBC N/A
- ATXS N/A
- 52 Week Low
- GCBC $25.25
- ATXS $6.64
- 52 Week High
- GCBC $37.25
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- GCBC 51.00
- ATXS 31.94
- Support Level
- GCBC $27.07
- ATXS $6.77
- Resistance Level
- GCBC $27.62
- ATXS $7.30
- Average True Range (ATR)
- GCBC 0.71
- ATXS 0.30
- MACD
- GCBC 0.16
- ATXS 0.02
- Stochastic Oscillator
- GCBC 77.95
- ATXS 14.66
About GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.